… Cervarix® product information: human papillomavirus vaccine type 16 and 18 (Recombinant
AS04 adjuvanted), 2007. Boronia, Victoria, Australia, 2007 (http://www.gsk.com.au/…

Prophylactic human papillomavirus (HPV) virus-like particle (VLP) vaccines are highly
effective. The available evidence suggests that neutralising antibody is the mechanism of …

… human papillomavirus (HPV) L1 (the major papillomavirus virion protein) virus-like particle
(VLP) vaccines are regarded as safe, effective, and well established prophylactic vaccines. …

Human papillomavirus (HPV) vaccines are now included in immunisation programmes in
71 countries. Unfortunately, uptake has been impacted in some countries by reduced …

… Costeffectiveness analysis of prophylactic human papillomavirus vaccination and screening
in Brazil. Poster presentation. 23rd International Papillomavirus Conference and Clinical …

… The availability of prophylactic human papillomavirus (HPV) vaccines has provided …
vaccines have each been licensed in over 100 countries. By the beginning of 2012, HPV vaccine …

… All available published articles or abstracts reporting the results of human studies of HPV
vaccines were reviewed for inclusion in this article. Additional information about ongoing …

… effect of a male vaccination program on female human papillomavirus (HPV) infection rates
and cervical cancer incidence, we needed to directly model the effect of vaccination on HPV …

… ’s (WHO) recommendations on the use of human papillomavirus (HPV) vaccines excerpted
from the WHO position paper on Human papillomavirus vaccines: WHO position paper, May …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …